A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

BACKGROUND: Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of patients are expected to respond to ICIs (Immune Checkpoint Inhibitors). In a clinical trial, combining the anti-TIGIT (T cell immunoreceptor with Ig and...

Descripción completa

Detalles Bibliográficos
Autores principales: Roussot, Nicolas, Fumet, Jean-David, Limagne, Emeric, Thibaudin, Marion, Hervieu, Alice, Hennequin, Audrey, Zanetta, Sylvie, Dalens, Lorraine, Fourrier, Théo, Galland, Loick, Jacob, Pierre, Bertaut, Aurélie, Rederstorff, Emilie, Chevalier, Cédric, Ghirardi, Sarah, Gilbert, Elodie, Khoukaz, Azzat, Martin, Etienne, Nicolet, Constance, Quivrin, Magali, Thibouw, David, Vulquin, Noémie, Truc, Gilles, Rouffiac, Magali, Ghiringhelli, Francois, Mirjolet, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633948/
https://www.ncbi.nlm.nih.gov/pubmed/37946136
http://dx.doi.org/10.1186/s12885-023-11534-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633948/
https://www.ncbi.nlm.nih.gov/pubmed/37946136
http://dx.doi.org/10.1186/s12885-023-11534-6

Ejemplares similares